Drug Trial Radar · NCT04790851
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,133
Actual
Start
Mar 10, 2021
Primary completion
Sep 5, 2021
Study completion Sep 5, 2021
Sponsor
- Lead sponsor
- China National Biotec Group Company LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Chengdu Institute of Biological Products Co.,Ltd.; Changchun Institute of Biological Products Co., Ltd.; Beijing Institute of Biological Products Co Ltd.; Sichuan Center for Disease Control and Prevention; Shanghai Municipal Center for Disease Control and Prevention; Centers for Disease Control and Prevention, China
- First posted
- Mar 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose: COVAX only, 2nd dose: COVAX only; Control Group B (384 subjects): 1st dose: IIV4 only, 2nd dose: PPV23 only. Blood samples will be collected 3 times: before the 1st dose of vaccinatioin; before the 2nd dose of vaccination; 28 days after the 2nd dose of vaccination. The immunogenicity and safety of both experimental and control groups will be analyzed.
Conditions
- Influenza, Human
- Pneumonia, Pneumococcal
- Covid19
Interventions
COVAX+IIV4; COVAX+PPV23Biological
1st dose : combined vaccination of COVAX+IIV4; 2nd dose: combined vaccination of COVAX+PPV23
COVAX only (1st and 2nd dose)Biological
1st dose: COVAX only; 2nd dose: COVAX only
IIV4 for the 1st dose and PPV23 for the 2nd doseBiological
1st dose: IIV4 only; 2nd dose: PPV23 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate (COVAX)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Seroconversion rate (COVAX)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
- Neutralizing antibody level (COVAX)Time frame: Baseline (before vaccination) results
- Neutralizing antibody level (COVAX)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Neutralizing antibody level (COVAX)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
- Seropositive rate (IIV4)Time frame: Baseline (before vaccination) results
- Seroconversion rate (IIV4)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Seroconversion rate (IIV4)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
- Hemmagglution inhibition antibody level (IIV4)Time frame: Baseline (before vaccination) results
- Hemmagglution inhibition antibody level (IIV4)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Hemmagglution inhibition antibody level (IIV4)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
- Seroconversion rate (PPV23)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Seroconversion rate (PPV23)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
- Neutralizing antibody level (PPV23)Time frame: Baseline (before vaccination) results
- Neutralizing antibody level (PPV23)Time frame: Results obtained 28 days after the first dose (= right before the second dose)
- Neutralizing antibody level (PPV23)Time frame: Results obtained after the second dose of vaccination (= 56 days after the first dose, or 28 days after the second dose)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sichuan Center for Disease Control and Prevention
Chengdu, China
Shanghai Municipal Center for Disease Control and Prevention
Shanghai, China
Shanxi Provincial Center for Disease Control and Prevention
Taiyuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.